股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 威發國際集團有限公司 呈交日期: 2026年2月3日 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00765 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 490,385,410 0 490,385,410 增加 / 減少 (-) 本月底結存 490,385,410 0 490,385,410 足夠公眾持股量的確認(註4) I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00765 | 說明 | | | | | | | | | | | 法 ...

Group 1 - The company Perfectech International (00765) announced the resignation of Mr. Li Shaohua as an executive director and authorized representative effective January 19, 2026 [1] - Mr. Zhong Shihui has been appointed as the authorized representative to succeed Mr. Li Shaohua [1] - Mr. Li Haiyang has been appointed as an executive director [1]

Group 1 - The company PERFECTECH INTL (00765) announced the resignation of Mr. Li Shaohua as an executive director and authorized representative effective January 19, 2026 [1] - Mr. Zhong Shihui has been appointed as the authorized representative to succeed Mr. Li Shaohua [1] - Mr. Li Haiyang has been appointed as an executive director [1]

Group 1 - The company PERFECTECH INTL (00765.HK) announced changes in its executive leadership effective January 19, 2026 [1] - Li Shaohua has resigned as an executive director and authorized representative [1] - Zhong Shihui has been appointed as the authorized representative to replace Li Shaohua [1] - Li Haiyang has been appointed as an executive director [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 PERFECTECH INTERNATIONAL HOLDINGS LIMITED 威發國際集團有限公司* （於百慕達註冊成立之有限公司） （股份編號：00765） （「本公司」） 潘偉業先生 董事名單與其角色和職能 本公司董事會（「董事會」）成員載列如下，由二零二六年一月十九日起生效： 鐘世輝先生 執行董事 李海洋先生 獨立非執行董事 提名委員會 劉樹人先生 （主席） 陳寶琳小姐 馮燦文先生 香港，二零二六年一月十九日 * 僅供識別 陳寶琳小姐 劉樹人先生 馮燦文先生 董事會設立三個委員會。各董事會成員於該等委員會中所擔任的職位載列如下： 審核委員會 劉樹人先生 （主席） 陳寶琳小姐 馮燦文先生 薪酬委員會 陳寶琳小姐 （主席） 劉樹人先生 馮燦文先生 – 1 – – 2 – ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 威發國際集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，自二零二六年 一月十九日起，李邵華先生因其他個人事務及業務承擔須投入更多精力，已辭任執 行董事以及香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第3.05 條項下的本公司授權代表（「授權代表」）。 李邵華先生已確認，彼與董事會並無任何意見分歧，亦無任何有關其辭任而需提請 本公司股東及聯交所垂注之事項，且彼並無就袍金、薪酬或有關彼不再擔任董事 – 1 – (i) 李邵華先生已辭任執行董事及授權代表； (ii) 鐘世輝先生已獲委任為授權代表，以接替李邵華先生；及 PERFECTECH INTERNATIONAL HOLDINGS LIMITED 威發國際集團有限公司* （於百慕達註冊成立之有限公司） （股份編號：00765） 變更執行董事 及授權代表 董事會宣佈，自二零二六年一月十九日起， (iii) 李海洋先生已獲委 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 重新提交 致：香港交易及結算所有限公司 公司名稱: 威發國際集團有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00765 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 700,000,000 | HKD | | 0.1 | HKD | | 70,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 700,000,000 | HKD | | 0.1 | HKD | | 70,000,000 | FF301 II. 已發行股 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 威發國際集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00765 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 700,000,000 | HKD | | | 0.1 HKD | | 70,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 700,000,000 | HKD | | | 0.1 HKD | | 70,000,000 | 本月底法定/註冊股本總額： H ...

Core Viewpoint - The company, Shiyao Innovation Pharmaceutical Co., Ltd. (stock code: 300765.SZ), has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor. The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [1]. Group 1: Company Overview - Shiyao Innovation has maintained its position as the world's largest producer of synthetic caffeine by revenue and shipment volume from 2020 to 2024, according to Frost & Sullivan [1]. - Since its establishment in 2006, the company has concentrated on the research and production of high-quality caffeine, primarily used as a food additive in functional beverages [1]. Group 2: Market Presence - As of the latest feasible date (December 1, 2025), the company's products have been sold in 65 countries and regions globally, with North America and Europe being its main markets [1]. - The company has established solid partnerships with leading international beverage industry clients, including Coca-Cola (since 2006), PepsiCo (since 2007), and Red Bull GmbH (since 2008), serving as their global caffeine supplier [1].

Group 1 - The company, Shiyao Innovation Pharmaceutical Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [1] - According to Frost & Sullivan, the company has maintained its position as the world's largest producer of synthetic caffeine by revenue and volume from 2020 to 2024 [1][5] Group 2 - Since its establishment in 2006, the company has specialized in the research and production of high-quality caffeine, primarily used as a food additive in functional beverages [5] - As of the last practicable date (December 1, 2025), the company's products have been sold in 65 countries and regions globally, with North America and Europe being its main markets [5] - The company has established solid partnerships with leading international beverage companies, including Coca-Cola (since 2006), PepsiCo (since 2007), and Red Bull GmbH (since 2008), serving as their global caffeine supplier [5]